A detailed history of Group One Trading, L.P. transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 11,064 shares of GOSS stock, worth $7,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,064
Holding current value
$7,744
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.79 - $1.25 $8,740 - $13,830
11,064 New
11,064 $10,000
Q4 2022

Feb 09, 2023

SELL
$1.74 - $12.87 $125,768 - $930,256
-72,281 Reduced 55.08%
58,938 $127,000
Q3 2022

Nov 09, 2022

SELL
$7.21 - $14.88 $21,521 - $44,416
-2,985 Reduced 2.22%
131,219 $1.57 Million
Q2 2022

Aug 11, 2022

BUY
$5.97 - $9.97 $756,184 - $1.26 Million
126,664 Added 1679.89%
134,204 $1.12 Million
Q1 2022

May 12, 2022

SELL
$8.44 - $12.49 $35,945 - $53,194
-4,259 Reduced 36.1%
7,540 $65,000
Q4 2021

Feb 11, 2022

SELL
$10.12 - $14.07 $22,375 - $31,108
-2,211 Reduced 15.78%
11,799 $133,000
Q3 2021

Nov 12, 2021

BUY
$7.25 - $13.23 $100,847 - $184,029
13,910 Added 13910.0%
14,010 $176,000
Q2 2021

Aug 10, 2021

BUY
$8.0 - $9.75 $800 - $975
100 New
100 $1,000
Q1 2021

May 12, 2021

SELL
$8.63 - $10.94 $43,909 - $55,662
-5,088 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$8.3 - $13.59 $40,670 - $66,591
4,900 Added 2606.38%
5,088 $49,000
Q3 2020

Nov 12, 2020

SELL
$11.3 - $14.75 $11,300 - $14,750
-1,000 Reduced 84.18%
188 $2,000
Q2 2020

Aug 13, 2020

SELL
$9.52 - $15.98 $573,170 - $962,107
-60,207 Reduced 98.06%
1,188 $15,000
Q1 2020

May 13, 2020

BUY
$8.0 - $15.48 $491,160 - $950,394
61,395 New
61,395 $623,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $65.8M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.